What Is NAD+

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell of the body that participates in hundreds of metabolic reactions, most critically in converting nutrients into usable cellular energy. It also serves as a required substrate for several families of enzymes involved in DNA repair, epigenetic regulation, and immune signaling. Cellular NAD+ levels decline measurably with age, making it a focal point of aging research.

NAD+ sits at the intersection of energy metabolism and cellular maintenance, two systems whose deterioration defines much of biological aging. When NAD+ levels fall, mitochondria produce energy less efficiently, DNA damage accumulates faster than it can be repaired, and inflammatory signaling increases. These downstream effects overlap with the hallmarks of aging that drive age-related disease, including metabolic dysfunction, neurodegeneration, and cardiovascular decline.

The longevity relevance of NAD+ extends beyond its role as a metabolic shuttle. It is the essential co-substrate for sirtuins, a family of enzymes that deacetylate proteins to regulate gene expression, stress responses, and mitochondrial biogenesis. It is also consumed by PARP enzymes during DNA repair and by CD38, an enzyme whose activity rises with chronic inflammation. The competition among these NAD+ consumers means that a decline in the total pool can create cascading functional losses across multiple organ systems simultaneously.

NAD+ participates in cellular chemistry in two fundamentally different ways. First, it acts as an electron carrier in redox reactions: it accepts electrons (becoming NADH) during glycolysis and the citric acid cycle, then donates them to the electron transport chain in mitochondria, where ATP is generated. This shuttle function is continuous and essential; without it, aerobic metabolism stops.

Second, NAD+ is consumed as a substrate by three major enzyme families. Sirtuins (SIRT1 through SIRT7) cleave NAD+ to remove acetyl groups from proteins, influencing gene expression, mitochondrial function, and inflammation. PARPs (poly ADP-ribose polymerases) use NAD+ to build repair scaffolds at sites of DNA damage. CD38, an ectoenzyme found on immune cells, degrades NAD+ as part of calcium signaling and immune activation. Each of these reactions destroys the NAD+ molecule, meaning the cell must continuously resynthesize it.

The body produces NAD+ through several biosynthetic routes. The salvage pathway recycles nicotinamide (a byproduct of sirtuin and PARP activity) back into NAD+ via the enzyme NAMPT, and this pathway handles the majority of NAD+ turnover in most tissues. The Preiss-Handler pathway converts nicotinic acid (niacin) into NAD+. The de novo pathway synthesizes NAD+ from tryptophan. Supplemental precursors like NMN and NR feed into these pathways at different entry points, with NMN entering just one enzymatic step from NAD+ and NR requiring conversion to NMN first via NR kinases.

NAD+ supplementation takes several forms, each with distinct pharmacokinetic profiles. Oral precursors, primarily NMN and NR, are the most widely available. NR is converted to NMN by nicotinamide riboside kinases, and NMN is then converted to NAD+ by NMNAT enzymes. Both effectively raise blood and tissue NAD+ levels, though the relative efficiency in specific tissues (brain, liver, muscle) may differ and remains an area of active research.

Direct oral NAD+ supplements exist but face significant bioavailability challenges because the NAD+ molecule is large and degrades in the gastrointestinal tract. Some formulations use enteric coatings or liposomal delivery to improve absorption, though independent validation of these claims is limited. Sublingual NAD+ preparations aim to bypass first-pass metabolism through mucosal absorption.

Intravenous NAD+ infusion delivers the coenzyme directly into the bloodstream, bypassing all absorption barriers. This method achieves the highest acute blood levels and is offered by many longevity and integrative medicine clinics. Infusions typically take one to several hours because rapid administration causes uncomfortable side effects. Intramuscular and subcutaneous NAD+ injections represent a middle ground, offering better bioavailability than oral forms with less time commitment than IV infusion.

Dosing for NAD+ precursors has not been standardized by any regulatory body, and recommendations are largely informed by the doses used in clinical trials. NMN has been studied at doses ranging from 250 mg to 1,250 mg daily, with most trials using 250 to 500 mg. NR has been studied at 100 mg to 2,000 mg daily, with 300 to 1,000 mg being the most common range in published trials. Both precursors show dose-dependent increases in NAD+ metabolites in blood.

Timing may matter. NAD+ biosynthesis follows a circadian pattern, with NAMPT expression peaking during the active phase. Taking precursors in the morning aligns with this natural rhythm and may support more efficient conversion. Some users report sleep disruption when taking NMN or NR late in the day, consistent with the energizing downstream effects of increased NAD+ availability.

For IV NAD+, clinical protocols typically use 250 to 750 mg per session for general wellness purposes, with some clinics administering higher doses for specific conditions. Sessions are usually spaced weekly or biweekly during a loading phase, then monthly for maintenance. There is no consensus on optimal frequency, and protocols vary considerably between practitioners.

The NAD+ precursor supplement market has grown rapidly, and product quality varies substantially. Third-party testing by organizations such as NSF International, USP, or independent analytical labs provides the most reliable assurance that a product contains what the label claims and is free of contaminants. Certificates of analysis (COAs) should be available from the manufacturer and should include purity testing (typically above 98% for NMN or NR), heavy metal screening, and microbial testing.

Stability is a meaningful concern for NMN in particular, as the molecule can degrade in the presence of heat and moisture. Products stored in opaque, moisture-sealed packaging with desiccants are preferable to those in clear bottles or bulk containers. Some manufacturers use cold-chain shipping for this reason. NR is generally considered more shelf-stable than NMN but should still be stored in cool, dry conditions.

Patented forms of NR (such as Niagen) have been used in the majority of published clinical trials, which provides a degree of traceability between the research evidence and the commercial product. For NMN, fewer patented forms have been studied in rigorous trials, making the connection between specific commercial products and published evidence less direct. Choosing products from manufacturers who participate in or fund clinical research offers an indirect quality signal, though it does not replace independent testing.

Animal research on NAD+ repletion is extensive and largely consistent. Studies in aged mice have demonstrated that boosting NAD+ through precursors like NMN or NR improves mitochondrial function, reverses age-related vascular dysfunction, enhances insulin sensitivity, and extends healthy lifespan in certain models. These results have been replicated across multiple laboratories and in several species.

Human evidence is still maturing. Multiple randomized controlled trials have confirmed that oral NMN and NR reliably increase circulating NAD+ levels in humans, with good short-term tolerability. However, clinical endpoints have been harder to demonstrate. Some trials have reported improvements in markers of muscle function, insulin sensitivity, or vascular health, while others have shown no significant benefit over placebo for the endpoints measured. No large, long-duration randomized trial has yet demonstrated that NAD+ precursor supplementation extends human healthspan or lifespan. The gap between robust animal data and mixed human results remains one of the central open questions in the field. Ongoing trials with larger sample sizes and longer follow-up periods are expected to clarify whether the biological effects seen in preclinical models translate to clinically meaningful human outcomes.

Short-term safety profiles for NMN and NR appear favorable in completed human trials, with gastrointestinal discomfort being the most commonly reported side effect. A theoretical concern, discussed in the research literature but not confirmed in clinical data, is that raising NAD+ could support the metabolism of existing tumor cells, since cancer cells also depend heavily on NAD+ for rapid growth. Individuals with active malignancies or a recent cancer history should discuss this consideration with their oncologist. Long-term safety data spanning years of continuous use does not yet exist. Intravenous NAD+ infusions carry additional risks related to infusion rate, including nausea, chest tightness, and cramping, and should be administered in a clinical setting with appropriate monitoring.